跳至主要内容
临床试验/EUCTR2004-002420-18-GB
EUCTR2004-002420-18-GB进行中(未招募)不适用

A prospective, non-randomised, non-controlled, open label, multicentre phase II study: PTK 787/ZK222584 in patients with advanced neuroendocrine tumours - PTK878/ZK 222584 in patients with advanced NET

CHARITE Universitätsmedizin Berlin Campus Virchow-Klinikum0 个研究点目标入组 35 人开始时间: 2005年3月16日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Measurable histologically and immunohistologically confirmed neuroendocrine tumour NET
  • 2) Tumour proliferation as measured by Ki67 15%
  • 3) Age > 18 years
  • 4) WHO performance status 0-2
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1) High grade NET (Ki67 > 15%)
  • 2) Chemotherapy 4 weeks prior to study entry
  • 3) Embolisation or Chemoembolisation less than 3 months prior to study entry
  • 4) Not recovered from surgery and no surgery within 2 weeks
  • 5) Embolisation in the previous 3 months
  • 6) Investigational drugs within 4 weeks
  • 7) Pregnant or breast feeding
  • 8) Adults in reproductive potential not using an effective method (ie barrier method) of birth control
  • 9) Other contraindication are listed in section 3.2.3 of the protocol

研究者

发起方
CHARITE Universitätsmedizin Berlin Campus Virchow-Klinikum

相似试验